Clinical evaluation of probucol in hypercholesterolemia: Individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression

Journal of Cardiovascular Pharmacology

Volumn 30, Issue 6, 1997, Pages 784-789

  Baldassarre, Damiano ^a   Franceschini, Guido ^a   Peruzzotti, Giulia ^a   Brusoni, Bruno ^b   Sirtori, Cesare R ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Carotid intimal medial thickness; HDL cholesterol; Hypercholesterolemia; LDL cholesterol; Probucol

Indexed keywords

BIFENABID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROBUCOL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; B SCAN; CAROTID ARTERY; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; CAROTID ARTERY DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROBUCOL; RETROSPECTIVE STUDIES;

EID: 0031425143     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199712000-00013     Document Type: Article

References (44)

1. Buckley MT, Goa KL, Price AH, Brogden RN, Probucol: a reappraisal of its pharmacological properties and therapeutic use in hypercholesterolemia. Drug 1989;37:761-800.
2. Sasahara M, Raines EW, Chait A, et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. J Clin Invest 1994;94:155-64.
3. Ishizaka N, Kurokawa K, Taguchi J, Miki K, Ohno M, Inhibitory effect of a single local probucol administration on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis 1995;118:53-6.
4. Naruszewicz M, Selinger E, Dufour R, Davignon J, Probucol protects lipoprotein(a) against oxidative modification. Metabolism 1992;41(11):1225-8.
5. Maeda S, Okuno M, Abe A, Noma A. Lack of effect of probucol on serum lipoprotein(a) levels. Atherosclerosis 1989;79:267-9.
6. Bagdade JD, Kaufman D, Ritter MC, Subbaiah PV. Probucol treatment in hypercholesterolemic patients: effects on lipoprotein composition, HDL particle size, and cholesteryl ester transfer. Atherosclerosis 1990;84:145-54.
7. Homma Y, Moriguchi EH, Sakane H, Ozawa H, Nakamura H, Goto Y. Effects of probucol on plasma lipoprotein subfractions and activities of lipoprotein lipase and hepatic triglyceride lipase. Atherosclerosis 1991;88:175-81.
8. Gordon DJ, Rifkind BM. High density lipoprotein: the clinical implications of recent studies. N Engl J Med 1989;321:1311-6.
9. 2 levels in myocardial infarction patients without risk factors for atherosclerosis. Atherosclerosis 1987;68:213-9.
10. Baker SG, Joffe BI, Mendelsohn D, Seftel HC. Treatment of homozygous familial hypercholesterolaemia with probucol. S Afr Med J 1982;62:7-11.
11. Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino BI. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 1986;57:29H-35H.
12. Franceschini G, Werba JP, Calabresi L. Drug control of reverse cholesterol transport. Pharmacol Ther 1994;61:289-324.
13. Franceschini G, Sirtori M, Vaccarino V, et al. Mechanisms of HDL reduction after probucol: changes in HDL subfractions and increased reverse cholesterol ester transfer. Arteriosclerosis 1989;9:462-9.
14. McPherson R, Hogue M, Milne RW, Tail AR, Marcell YL. Increase in plasma cholesteryl ester transfer protein during probucol treatment: relation to changes in high density lipoprotein composition. Arterioscler Thromb 1991;11:476-81.
15. Saku K, Zhang B, Hirata K, et al. Combined therapy with probucol and pravastatin in hypercholesterolaemia: one year follow-up study. Eur J Clin Pharmacol 1993;44:535-9.
16. Dujovne CA, Krehbiel P, Decoursey S, et al. Probucol with colestipol in the treatment of hypercholesterolemia. Ann Intern Med 1984;100:447-82.
17. Ohya Y, Kumamoto K, Abe I, Tsubota Y, Fujishima M. Factors related to QT interval prolongation during probucol. Eur J Clin Pharmacol 1993;45:47-52.
18. Strandberg TE, Salomaa UV, Naukkarinen VA, Vanhanen HT, Sarna SJ, Miettnen TA. Cardiovascular morbidity and multifactorial primary prevention: fifteen-year follow-up of the Helsinki Businessmen Study. Nutr Metab Cardiovasc Dis 1995;5:7-15.
19. Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994;74:875-83.
20. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332(8):488-93.
21. National Cholesterol Education Program Second Report of the expert panel. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994;89 (3):1329-80.
22. Bertolini S, Lelli N, Coviello DA, et al. A large deletion in the LDL receptor gene - the cause of familial hypercholesterolemia in three Italian families: a study that dates back to the 17th century (FH-Pavia). Am J Hum Genet 1992;51(1):123-34.
23. Grundy SM, Chait A, Brunzell JD. Familial combined hyperlipidemia workshop. Arteriosclerosis 1987;7:203-7.
24. Warnick GR, Benderson J, Albers JJ. Dextran sulfate precipitation procedure for quantitation of high density lipoproteins. Clin Chem 1982;28:1379-88.
25. Werba JP, Safa O, Gianfranceschi G, Michelagnoli S, Sirton CR, Franceschini G. Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population. Atherosclerosis 1993;101:203-11.
26. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intima plus media thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986;74(6):1399-406.
27. Poli A, Tremoli E, Colombo A, Sirtori M, Pignoli P, Paoletti R. Ultrasonographic measurement of the common carotid artery wall thickness in hypercholesterolemic patients: a new model for the quantitation and follow-up of pre-clinical atherosclerosis in living human subjects. Atherosclerosis 1988;70:253-61.
28. Baldassarre D, Werba JP, Tremoli E, Poli A, Pazzucconi F, Sirtori C. Common carotid intima-media thickness measurement: a method to improve accuracy and precision. Stroke 1994;25:1588-92.
29. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995;91:10-5.
30. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5.
31. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
32. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996;97(12):2917-23.
33. 2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia: a Probucol Quantitative Regression Swedish Trial (PQRST) report. Arterioscler Thromb Vasc Biol 1995;15:1049-56.
34. Margitic SE, Bond MG, Crouse JR, Furberg CD, Probstfield JL. Progression and regression of carotid atherosclerosis in clinical trials. Arterioscler Thromb 1991;11(2):443-51.
35. Furberg CD, Adams HP, Applegate WB, et al. for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994;90:1679-87.
36. Salonen R, Nyyssönen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary prevention trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995;92(7):1758-64.
37. Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study (CAIUS). Am J Med 1996;101:627-34.
38. Blankenhorn DH, Azen SP, Crawford DW, et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation 1991;83:438-47.
39. Kakuta T, Currier JW, Haudenschild CC, Ryan TJ, Faxon DP. Differences in compensatory vessel enlargement, not intimai formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation 1994;89(6):2809-15.
40. Raal FJ, Areias AJ, Pilcher GJ, Joffe BI, Seftel HC. Lack of effect of high dose vitamin E on xanthoma regression in homozygous familial hypercholesterolemia. Atherosclerosis 1994;107:213-9.
41. Pazzucconi F, Dorigotti F, Gianfranceschi G, et al. Therapy with HMG-CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity. Atherosclerosis 1995; 117:189-98.
42. Davignon J. Medical management of hyperlipidemia and the role of probucol. Am J Cardiol 1986;57:22H-8H.
43. Lee YJ, Daida H, Yokoi H. et al. Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. Jpn Heart J 1996;37(3):327-32.
44. Tardif J-C. Côté G, Lespérance J. et al. Probucol and multivitamins in the prevention of resterosis after coronary angioplasty. N Engl J Med 1997;337:365-72.